Home THIS WEBSITE IS INTENDED FOR HEALTHCARE PROFESSIONALS (HCPs) ONLY

Sylvant logo Menu

Clinical Paper Request

The following papers have been published. To request a copy of the paper, please click on the title which
will send a request to EUSA Pharma medical information.

Siltuximab for multicentric Castleman’s disease: a randomised, double-blind, placebo-controlled trial. van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Fossa A, et al.
Lancet Oncol. 2014;15(9):966-74. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, et al.
Blood. 2017;129(12):1646-57. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.van Rhee F, Voorhees R, Dispenzieri A, Fosså A, Srkalovic G, Ide M, et al.
Blood. 2018;132(15): 2115-24.

To find out more about EUSA Pharma privacy practices view the Privacy Policy


 

Diagnosis

Diagnosis

Idiopathic Multicentric Castleman Disease (iMCD) is a rare and devasting disease

MORE
Efficacy

Efficacy

Pivotal Phase 2 Study

MORE
Tolerability

Tolerability

Adverse reactions and safety

MORE
Mode of Action

Mode of Action

Understanding the mechanism of action of SYLVANT®

MORE
Dosing & Administration

Dosing & Administration

Recommended dosing of SYLVANT®

MORE
Clinical Papers

Clinical Papers

Request published clinical papers

MORE

 

Join our mailing list
Enter your email to receive email alerts when new content is added to this website

SUBMIT

© 2020 EUSA Pharma
Date of prep: April 2020
GL-SIL-2000025
EUSA Sylvant

This medicinal product is subject to additional monitoring.
Adverse events to medicinal products should be reported.
Reporting forms and information can be found at your local health authority website.
To report a potential adverse event with an EUSA product please send an email to safety@eusapharma.com.
This website is developed and funded by EUSA for healthcare professionals only.
This website will not collect any personal or private information.

© 2020 EUSA Pharma - Registered in England No. 9329429
Registered office: Breakspear Park, Breakspear Way, Hemel Hempstead, Hertfordshire, HP2 4TZ